sacituzumab govitecan
gilead sciences
['bcsm', 'mbc', ' sg ', 'tropics02']
tropics02: saci vs tpc in heavily pretreated hr+her2- mbc 34% reduction in risk of disease progression, hr 0.66 at 12m, pfs w/ sg was 21% vs 7% w/ tpc safety w/ sg manageable &amp; no new concerns overall hrqol benefit noted w/ sg os immature #asco2022 #bcsm 
Breast Medical Oncologist @UNC_Lineberger Prior @JCO_ASCO editorial fellow. Views are my own.